US panel knocks efficacy of Arpida's iclaprim for skin infections
This article was originally published in Scrip
The US FDA's outside advisors soundly recommended against approval of Arpida's iclaprim on November 20th, saying the company failed to establish that the antibacterial's efficacy was non-inferior to linezolid in treating complicated skin and skin structure infections (cSSSI).
You may also be interested in...
Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA
Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI, Motif needs to raise funds and fast to stay afloat and prepare a meeting package to discuss the next steps for iclaprim with the agency.
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
The latest drug development news and highlights from our US FDA Performance Tracker.
Motif Bio Seeks Cash For Novel Antibiotic
Motif Bio wants to raise £19.4m to further develop iclaprim, its novel antibiotic candidate for acute bacterial skin and skin structure infections.